lncRNA‑CCHE1 is involved in migration and invasion but not in proliferation of pancreatic adenocarcinoma cells possibly by interacting with ROCK1

Jin,Xiang; Ye,Liping; Lin,Minhua; Gu,Binbin; Wang,Jun; He,Yequn; Li,Weilin

doi:10.3892/ol.2019.10416

lncRNA‑CCHE1 is involved in migration and invasion but not in proliferation of pancreatic adenocarcinoma cells possibly by interacting with ROCK1

Authors:
- Xiang Jin
- Liping Ye
- Minhua Lin
- Binbin Gu
- Jun Wang
- Yequn He
- Weilin Li
View Affiliations

Affiliations: Department of Gastroenterology, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou, Zhejiang 317000, P.R. China, Department of Urology, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou, Zhejiang 317000, P.R. China
Published online on: May 30, 2019 https://doi.org/10.3892/ol.2019.10416
Pages: 1218-1224
Copyright: © Jin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical carcinoma high‑expressed long non‑coding RNA (lncRNA) 1 (lncRNA‑CCHE1) serves an oncogenic role in cervical and liver cancer. The present study aimed to explore the role of CCHE1 in pancreatic adenocarcinoma. CCHE1 expression was detected by reverse transcription‑quantitative polymerase chain reaction, and rho associated coiled‑coil containing protein kinase 1 (ROCK1) levels were detected using an ELISA assay. Diagnostic analysis was performed by receiver operating characteristic curve analysis. The effects of CCHE1 on ROCK1 were analyzed by western blotting. Cell migration and invasion were analyzed by Transwell migration and invasion assays. The results of the present study demonstrated that, compared with healthy controls, CCHE1 and ROCK1 were upregulated in the serum of patients with metastatic pancreatic adenocarcinoma. CCHE1 overexpression distinguished patients with metastatic pancreatic adenocarcinoma from patients with non‑metastatic pancreatic adenocarcinoma and healthy controls. A significant positive correlation between serum levels of CCHE1 and ROCK1 was identified in patients with metastatic pancreatic adenocarcinoma. Furthermore, CCHE1 overexpression led to upregulated ROCK1 in human pancreatic adenocarcinoma cell lines, whereas no significant effects of ROCK1 overexpression upon CCHE1 expression were identified. CCHE1 overexpression promoted the migration and invasion of human pancreatic adenocarcinoma cell lines, but no significant effects on cell proliferation were identified. ROCK1 small interfering RNA‑induced silencing partially reversed the enhancing effects of CCHE1 overexpression on cancer cell migration and invasion. Therefore, lncRNA‑CCHE1 may be involved in migration and invasion but not in proliferation of pancreatic adenocarcinoma cells, possibly by interacting with ROCK1.

View Figures

View References

1	Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
2	Malvezzi M, Bertuccio P, Levi F, La Vecchia C and Negri E: European cancer mortality predictions for the year 2014. Ann Oncol. 25:1650–1656. 2014. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
4	Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O'Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, et al: Metastatic pancreatic cancer: American Society of clinical oncology clinical practice guideline. J Clin Oncol. 34:2784–2796. 2016. View Article : Google Scholar : PubMed/NCBI
5	Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74:2913–2921. 2014. View Article : Google Scholar : PubMed/NCBI
6	Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM III, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, et al: Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol. 33:4039–4047. 2015. View Article : Google Scholar : PubMed/NCBI
7	Amano M, Fukata Y and Kaibuchi K: Regulation and functions of Rho-associated kinase. Exp Cell Res. 261:44–51. 2000. View Article : Google Scholar : PubMed/NCBI
8	Lochhead PA, Wickman G, Mezna M, Mezna M and Olson MF: Activating ROCK1 somatic mutations in human cancer. Oncogene. 29:2591–2598. 2010. View Article : Google Scholar : PubMed/NCBI
9	Gilkes DM, Xiang L, Lee SJ, Chaturvedi P, Hubbi ME, Wirtz D and Semenza GL: Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. Proc Natl Acad Sci USA. 111:E384–E393. 2014. View Article : Google Scholar : PubMed/NCBI
10	Rath N and Olson MF: Rho-associated kinases in tumorigenesis: Re-considering ROCK inhibition for cancer therapy. EMBO Rep. 13:900–908. 2012. View Article : Google Scholar : PubMed/NCBI
11	Li J, Song Y, Wang Y, Luo J and Yu W: MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells. Mol Cell Biochem. 380:277–282. 2013. View Article : Google Scholar : PubMed/NCBI
12	Yang M, Zhai X, Xia B, Wang Y and Lou G: Long noncoding RNA CCHE1 promotes cervical cancer cell proliferation via upregulating PCNA. Tumuor Biol. 36:7615–7622. 2015. View Article : Google Scholar
13	Peng W and Fan H: Long noncoding RNA CCHE1 indicates a poor prognosis of hepatocellular carcinoma and promotes carcinogenesis via activation of the ERK/MAPK pathway. Biomed Pharmacother. 83:450–455. 2016. View Article : Google Scholar : PubMed/NCBI
14	Kamarajah SK, Burns WR, Frankel TL, Cho CS and Nathan H: Validation of the American Joint Commission on Cancer (AJCC) staging system for patients with pancreatic adenocarcinoma: A surveillance, epidemiology and end results (SEER) analysis. Ann Surg Oncol. 24:2023–2030. 2017. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, et al: Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 138:958–968. 2010. View Article : Google Scholar : PubMed/NCBI
17	Chisholm KM, Wan Y, Li R, Montgomery KD, Chang HY and West RB: Detection of long non-coding RNA in archival tissue: Correlation with polycomb protein expression in primary and metastatic breast carcinoma. PLoS One. 7:E479982012. View Article : Google Scholar : PubMed/NCBI
18	Vigil D, Kim TY, Plachco A, Garton AJ, Castaldo L, Pachter JA, Dong H, Chen X, Tokar B, Campbell SL and Der CJ: ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res. 72:5338–5347. 2012. View Article : Google Scholar : PubMed/NCBI
19	Shields MA, Krantz SB, Bentrem DJ, Dangi-Garimella S and Munshi HG: Interplay between β1-integrin and Rho signaling regulates differential scattering and motility of pancreatic cancer cells by snail and Slug proteins. J Biol Chem. 287:6218–6229. 2012. View Article : Google Scholar : PubMed/NCBI
20	Wang Y, Zeng X, Wang N, Zhao W, Zhang X, Teng S, Zhang Y and Lu Z: Long noncoding RNA DANCR, working as a competitive endogenous RNA, promotes ROCK1-mediated proliferation and metastasis via decoying of miR-335-5p and miR-1972 in osteosarcoma. Mol Cancer. 17:892018. View Article : Google Scholar : PubMed/NCBI
21	Wang H, Zhang M and Sun G: Long non-coding RNA NEAT1 regulates the proliferation, migration and invasion of gastric cancer cells via targeting miR-335-5p/ROCK1 axis. Pharmazie. 73:150–155. 2018.PubMed/NCBI